N4 Pharma PLC reports change in major shareholding

Published 23/04/2025, 14:36
N4 Pharma PLC reports change in major shareholding

LONDON - N4 Pharma PLC, a pharmaceutical company, has experienced a significant shift in its shareholder structure, as announced on April 23, 2025. Nigel James Theobald, previously holding a 4.30% stake in the company, has seen his share of voting rights decrease to 2.04%.

This change occurred on the same day, following a placement that increased the company’s issued share capital, as previously disclosed on June 7. Theobald’s direct voting rights in N4 Pharma PLC now correspond to 16,981,319 shares, according to the regulatory filing with the London Stock Exchange (LON:LSEG).

The notification, a standard TR-1 form for major holdings, indicates that Theobald does not control any other undertakings that hold an interest in N4 Pharma PLC, nor is he controlled by any other natural person or legal entity in relation to these holdings.

The total number of voting rights in the company now stands at 832,280,349. The filing did not indicate any acquisition or disposal of financial instruments that could affect the percentage of voting rights.

N4 Pharma PLC specializes in the development and commercialization of novel pharmaceutical formulations. The company’s shares are traded on the London Stock Exchange, and this latest development may be of interest to investors and market watchers.

The information for this report is based on a press release statement distributed by RNS, the news service of the London Stock Exchange.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.